Genap­sys fi­nal­ly un­veils vaunt­ed se­quencer, but can it dent Il­lu­mi­na?

6 years ago
R&D

Ex-Ed­i­tas CEO Ka­trine Bosley chairs Ar­rakis board; Car­du­ri­on touts Po­laris in­vest­ment

6 years ago
News Briefing

Ahead of strate­gic up­date, new Sanofi CEO mulls op­tions for con­sumer health­care arm — re­ports

6 years ago
Deals
Pharma

Brii Bio backs in­fec­tious dis­ease start­up while ink­ing deal for its lead TB drug, dou­bling down on an­tibi­otics

6 years ago
Deals
China

The triple crown in biotech: An all-or-noth­ing bet on an FDA ap­proval of 3 drugs over 16 months starts to­day

6 years ago
R&D

No­var­tis, Bay­er, Long­wood back ge­nomics start­up to speed search for im­munother­a­py tar­gets

6 years ago
Startups
R&D

Ab­b­Vie scoops up op­tion to li­cense Har­poon's BC­MA drug for $50M up­front as biotech part­ner preps PhI/II tri­al

6 years ago
Deals

Can­cer Re­search UK spin­off rais­es $41M+ in Se­ries B in­jec­tion

6 years ago
Financing
Startups

Mor­phoSys’ chief sci­en­tist hits the ex­it, trig­ger­ing R&D re­or­ga­ni­za­tion as they shift fo­cus to US in an­tic­i­pa­tion ...

6 years ago
People
R&D

Make that 2 ap­proved RNAi drugs at Al­ny­lam af­ter the FDA of­fers a speedy OK on ul­tra-rare dis­ease drug

6 years ago
R&D

Stephen Hahn gets through Sen­ate’s soft­ball job in­ter­view — but most­ly plays dodge­ball on the is­sues fac­ing the ...

6 years ago
Bioregnum
Opinion

Ac­tivist in­vestor wages suit on On­coSec over re­cent deal; Breast can­cer ex­perts de­but biotech with $12M seed

6 years ago
News Briefing

Op­di­vo/Yer­voy com­bo for melanoma fails in key pa­tient pop­u­la­tion

6 years ago
R&D

Eli Lil­ly touts $400M man­u­fac­tur­ing ex­pan­sion, 100 new jobs to much fan­fare in In­di­anapo­lis — even though it's been ...

6 years ago
Pharma

Ver­tex's stel­lar quar­ter car­ries on with French re­im­burse­ment deal

6 years ago
R&D

Kymera hands the helm to No­var­tis vet — and found­ing CSO — Nel­lo Main­olfi

6 years ago
R&D

MPM and Long­wood-backed Were­wolf Ther­a­peu­tics grabs $56 mil­lion to take tu­mors by night

6 years ago
Financing

Lon­don's bio­phar­ma-fo­cused GHO Cap­i­tal Part­ners claims close of largest-ever Eu­ro­pean fund

6 years ago
Financing

Am­gen chops 172 more staffers in R&D, op­er­a­tions and sales amid neu­ro­science ex­it, rev­enue down­turn

6 years ago
People

Ab­b­Vie lines up a new pre­clin­i­cal R&D al­liance with the deal­mak­ers at nat­ur­al killer play­er Drag­on­fly

6 years ago
R&D

With eyes on a poly­mer em­pire prize, French medtech play­er seals $42M in fresh fund­ing

6 years ago
Startups

As­traZeneca los­es an­oth­er ex­ec­u­tive to biotech, as Badrul Chowd­hury moves to Savara

6 years ago
People
Pharma

Alk­er­mes sub­mits long await­ed NDA for schiz­o­phre­nia, bipo­lar drug; Is a uni­corn bub­ble drag­ging the IPO mar­ket?

6 years ago
News Briefing

No­var­tis is eye­ing a multi­bil­lion-dol­lar Med­Co buy­out as Jer­sey biotech nears NDA — re­ports

6 years ago
R&D
First page Previous page 891892893894895896897 Next page Last page
A service from the Financial Times